Form 4 for CYTK CYTOKINETICS INC
Accepted 2025-01-21 00:00:00 ET · period of report 2025-01-21 · accession 0001127602-25-001636 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-21 | 2025-01-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $10.60 | +2,000 | 118.1K | +2% | +$21.2K |
| D | 2025-01-21 | 2025-01-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $45.92 | -2,000 | 116.1K | -2% | -$91.8K |
| D | 2025-01-21 | 2025-01-21 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $0.00 | -2,000 | 37.1K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-21 | M | A | 2,000 | $10.60 | 118,071 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-21 | S | D | 2,000 | $45.92 | 116,071 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2025-01-21 | M | D | 2,000 | $0.00 | 37,105 | D | $10.60 · 2017-03-28 to 2027-02-28 | 2,000 Common Stock |